-
FDA panel backs Contrave
SAN DIEGO — A Food and Drug Administration advisory committee has recommended approval for an investigational diet pill.
Orexigen Therapeutics and Takeda Pharmaceutical announced Tuesday that the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13-7 that clinical trial data demonstrated that the benefits of the drug Contrave (naltrexone and bupropion) outweighed its risk and supported approval. The committee also voted 11-8 to recommend a study to examine Contrave’s effect on risk for cardiac disease.
-
Women with diabetes may suffer from low sex drive, study finds
CARY, N.C. — Almost half of women in the United States who suffer from diabetes reported that it has a negative impact on their sex lives, according to a new study released Tuesday by MicroMass Communications.
The research, which highlighted the need for improved education and support to help women build confidence in their ability to overcome the challenges of the disease, was conducted with a representative sample of more than 800 women with diabetes.